Ovoca Bio
Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health, particularly developing novel treatments for conditions like hypoactive sexual desire disorder (HSDD). The company operates in Ireland and the UK, and is dedicated to addressing high unmet medical needs through innovative medicines. Their lead product candidate, Orenetide, is a synthetic peptide administered via nasal spray, showing promising results in clinical trials for HSDD in premenopausal women. Ovoca Bio owns a broad patent portfolio and aims to become a leader in women’s health research and development, collaborating with global pharmaceutical partners to accelerate the availability of their treatments.
Industries
Nr. of Employees
small (1-50)
Ovoca Bio
17 Pembroke Street Upper, Dublin 2 D02 AT22, Ireland
Products
Lead synthetic peptide nasal‑spray candidate for HSDD (premenopausal women)
A synthetic peptide therapeutic formulated as a nasal spray intended to treat hypoactive sexual desire disorder in premenopausal women; clinical development includes Phase I, pivotal Phase II and Phase III studies with reported improvements in sexual desire, satisfying sexual events and distress measures.
Lead synthetic peptide nasal‑spray candidate for HSDD (premenopausal women)
A synthetic peptide therapeutic formulated as a nasal spray intended to treat hypoactive sexual desire disorder in premenopausal women; clinical development includes Phase I, pivotal Phase II and Phase III studies with reported improvements in sexual desire, satisfying sexual events and distress measures.
Services
Evaluation and negotiation of licensing or collaboration agreements with pharmaceutical companies and regional partners to support development and commercialisation.
Recruitment and management of volunteers for interventional studies evaluating intranasal peptide therapy for HSDD, including registry listing and site coordination.
Preparation and submission of regulatory applications for marketing approval in multiple jurisdictions and coordination of regulatory strategy.
Evaluation and negotiation of licensing or collaboration agreements with pharmaceutical companies and regional partners to support development and commercialisation.
Recruitment and management of volunteers for interventional studies evaluating intranasal peptide therapy for HSDD, including registry listing and site coordination.
Preparation and submission of regulatory applications for marketing approval in multiple jurisdictions and coordination of regulatory strategy.
Expertise Areas
- Clinical trial management
- Peptide therapeutics development
- Intranasal drug delivery
- Regulatory strategy and marketing authorisation
Key Technologies
- Synthetic peptide therapeutics
- Intranasal (nasal‑spray) delivery
- Phase I–III clinical trial methodologies
- Validated clinical endpoints for sexual function (e.g., FSFI, FSDS‑R)
News & Updates
The 2024 Annual General Meeting of Ovoca Bio will be held at Buswells Hotel, Dublin, Ireland on December 18, 2024.
Ovoca Bio published its 2024 Annual Report.
The 2024 Annual General Meeting of Ovoca Bio will be held at Buswells Hotel, Dublin, Ireland on December 18, 2024.
Ovoca Bio published its 2024 Annual Report.